Revolutionizing ADHD Care: Unlocking the Potential of Technology
The world of ADHD diagnosis and treatment is evolving, and technology is at the forefront. But how do we ensure that these advancements benefit patients without compromising diagnostic accuracy? This is the question at the heart of a recent study presented at the American Professional Society of ADHD and Related Disorders (APSARD) 2026 Annual Conference.
Dr. Barry Herman, MD, delved into the real-world application of an online ADHD assessment tool and telepsychiatry, sparking discussions about the role of technology in ADHD care. With nearly half of adults with ADHD utilizing telehealth, the study aimed to bridge a critical gap in evidence by comparing telehealth-based diagnostic tools with traditional clinical interviews.
But here's where it gets controversial: While telehealth has gained popularity, concerns about diagnostic rigor and stimulant prescribing have also emerged. Some companies have been criticized for their approach to ADHD diagnosis and treatment, casting a shadow on the entire field of telehealth.
Dr. Herman's study, published in the Journal of Clinical Psychiatry, found that their online asynchronous assessment had a high degree of agreement with a diagnostic clinical interview, with 80% sensitivity and a positive predictive value of 95%. This is a significant finding, especially considering the variability in ADHD diagnosis in the real world.
And this is the part most people miss: The study highlights the importance of human judgment in the diagnostic process. Despite the potential of technology, there are currently no accessible biomarkers for ADHD diagnosis. The study emphasizes the need for clinical oversight and the role of experienced clinicians in interpreting data and making informed decisions.
When asked about the tool's ability to handle diagnostic complexity, Dr. Herman explained that it can identify commonly associated mental health conditions with ADHD. However, the human element remains crucial, as clinicians use the data to further explore and understand the patient's clinical presentation.
AI in the spotlight: Addressing concerns about artificial intelligence, Dr. Herman assured that their company has established an AI ethics committee. He emphasized that their diagnostic process involves human judgment, not chatbots or AI making diagnoses. This human-centric approach is vital in maintaining the trust and confidence of both practitioners and patients.
Dr. Herman's motivation? Helping people and improving lives. With a background in the pharmaceutical industry, he now finds himself closer to the individual patient encounter, making a tangible impact on people's lives.
This study marks a significant step towards integrating technology into ADHD care while maintaining clinical rigor. As the field of telehealth continues to evolve, studies like this will play a pivotal role in shaping the future of ADHD diagnosis and treatment.
